Jaina M. Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jaina M. Patel has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Periasamy Selvaraj
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
9 shared publications Vincent F. Vartabedian
Department of Pathology, Emory University School of Medicine , Atlanta, Georgia, USA
5 shared publicationsErica N. Bozeman
Department of Pathology, Emory University School of Medicine , Atlanta, Georgia, USA
3 shared publicationsPeriasamy Selvaraj
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322
3 shared publications- Erica N. Bozeman
Department of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA USA
2 shared publications Paulami Dey
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
2 shared publications
Latest Publications
- 12 June 2020
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 16 (12) , 3184-3193
Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer
Triple-negative breast cancer (TNBC) afflicts women at a younger age than other breast cancers and is associated with a worse clinical outcome. This poor clinical outcome is attributed to a lack of defined targets and patient-to-patient heterogeneity in target antigens and immune responses. To address such heterogeneity, we tested the efficacy of a personalized vaccination approach for the treatment of TNBC using the 4T1 murine TNBC model. We isolated tumor membrane vesicles (TMVs) from homogenized 4T1 tumor tissue and incorporated glycosyl phosphatidylinositol (GPI)-anchored forms of the immunostimulatory B7-1 (CD80) and IL-12 molecules onto these TMVs to make a TMV vaccine. Tumor-bearing mice were then administered with the TMV vaccine either alone or in combination with immune checkpoint inhibitors. We show that TMV-based vaccine immunotherapy in combination with anti-CTLA-4 mAb treatment upregulated immunomodulatory cytokines in the plasma, significantly improved survival, and reduced pulmonary metastasis in mice compared to either therapy alone. The depletion of CD8+ T cells, but not CD4+ T cells, resulted in the loss of efficacy. This suggests that the vaccine acts via tumor-specific CD8+ T cell immunity. These results suggest TMV vaccine immunotherapy as a potential enhancer of immune checkpoint inhibitor therapies for metastatic triple-negative breast cancer.
- 12 June 2020
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 16 (12) , 3184-3193
Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer
Triple-negative breast cancer (TNBC) afflicts women at a younger age than other breast cancers and is associated with a worse clinical outcome. This poor clinical outcome is attributed to a lack of defined targets and patient-to-patient heterogeneity in target antigens and immune responses. To address such heterogeneity, we tested the efficacy of a personalized vaccination approach for the treatment of TNBC using the 4T1 murine TNBC model. We isolated tumor membrane vesicles (TMVs) from homogenized 4T1 tumor tissue and incorporated glycosyl phosphatidylinositol (GPI)-anchored forms of the immunostimulatory B7-1 (CD80) and IL-12 molecules onto these TMVs to make a TMV vaccine. Tumor-bearing mice were then administered with the TMV vaccine either alone or in combination with immune checkpoint inhibitors. We show that TMV-based vaccine immunotherapy in combination with anti-CTLA-4 mAb treatment upregulated immunomodulatory cytokines in the plasma, significantly improved survival, and reduced pulmonary metastasis in mice compared to either therapy alone. The depletion of CD8+ T cells, but not CD4+ T cells, resulted in the loss of efficacy. This suggests that the vaccine acts via tumor-specific CD8+ T cell immunity. These results suggest TMV vaccine immunotherapy as a potential enhancer of immune checkpoint inhibitor therapies for metastatic triple-negative breast cancer.
- Open Access
- 7 November 2016
- Published by American Society for Cell Biology (ASCB) in Molecular Biology of the Cell
- Vol. 27 (22) , 3449-3458
Effects of anchor structure and glycosylation of Fcγ receptor III on ligand binding affinity
Isoforms of the Fcγ receptor III (FcγRIII or CD16) are cell surface receptors for the Fc portion of IgG and important regulators of humoral immune responses. Different ligand binding kinetics of FcγRIII isoforms are obtained in three dimensions by surface plasmon resonance and in two dimensions by a micropipette adhesion frequency assay. We show that the anchor structure of CD16 isoforms isolated from the cell membrane affects their binding affinities in a ligand-specific manner. Changing the receptor anchor structure from full to partial to none decreases the ligand binding affinity for human IgG1 (hIgG1) but increases it for murine IgG2a (mIgG2a). Removing N-glycosylation from the CD16 protein core by tunicamycin also increases the ligand binding affinity. Molecular dynamics simulations indicate that deglycosylation at Asn-163 of CD16 removes the steric hindrance for the CD16-hIgG1 Fc binding and thus increases the binding affinity. These results highlight an unexpected sensitivity of ligand binding to the receptor anchor structure and glycosylation and suggest their respective roles in controlling allosterically the conformation of the ligand binding pocket of CD16.
- 7 November 2016
- Published by American Society for Cell Biology (ASCB) in Molecular Biology of the Cell
- Vol. 27 (22) , 3449-3458
Open AccessEffects of anchor structure and glycosylation of Fcγ receptor III on ligand binding affinity
Isoforms of the Fcγ receptor III (FcγRIII or CD16) are cell surface receptors for the Fc portion of IgG and important regulators of humoral immune responses. Different ligand binding kinetics of FcγRIII isoforms are obtained in three dimensions by surface plasmon resonance and in two dimensions by a micropipette adhesion frequency assay. We show that the anchor structure of CD16 isoforms isolated from the cell membrane affects their binding affinities in a ligand-specific manner. Changing the receptor anchor structure from full to partial to none decreases the ligand binding affinity for human IgG1 (hIgG1) but increases it for murine IgG2a (mIgG2a). Removing N-glycosylation from the CD16 protein core by tunicamycin also increases the ligand binding affinity. Molecular dynamics simulations indicate that deglycosylation at Asn-163 of CD16 removes the steric hindrance for the CD16-hIgG1 Fc binding and thus increases the binding affinity. These results highlight an unexpected sensitivity of ligand binding to the receptor anchor structure and glycosylation and suggest their respective roles in controlling allosterically the conformation of the ligand binding pocket of CD16.
- 1 January 2016
- Published by Elsevier in Biomaterials
- Vol. 74, 231-244
Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth
- 1 January 2016
- Published by Elsevier in Biomaterials
- Vol. 74, 231-244
Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth
- 6 March 2015
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 11 (5) , 1097-1107
Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses
- 6 March 2015
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 11 (5) , 1097-1107
Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses
- 16 February 2015
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 112 (6) , 1102-1110
Influenza virus‐like particles engineered by protein transfer with tumor‐associated antigens induces protective antitumor immunity
Delivery of antigen in particulate form using either synthetic or natural particles induces stronger immunity than soluble forms of the antigen. Among naturally occurring particles, virus‐like particles (VLPs) have been genetically engineered to express tumor‐associated antigens (TAAs) and have shown to induce strong TAA‐specific immune responses due to their nano‐particulate size and ability to bind and activate antigen‐presenting cells. In this report, we demonstrate that influenza VLPs can be modified by a protein transfer technology to express TAAs for induction of effective antitumor immune responses. We converted the breast cancer HER‐2 antigen to a glycosylphosphatidylinositol (GPI)‐anchored form and incorporated GPI‐HER‐2 onto VLPs by a rapid protein transfer process. Expression levels on VLPs depended on the GPI‐HER‐2 concentration added during protein transfer. Vaccination of mice with protein transferred GPI‐HER‐2‐VLPs induced a strong Th1 and Th2‐type anti‐HER‐2 antibody response and protected mice against a HER‐2‐expressing tumor challenge. The Soluble form of GPI‐HER‐2 induced only a weak Th2 response under similar conditions. These results suggest that influenza VLPs can be enriched with TAAs by protein transfer to develop effective VLP‐based subunit vaccines against cancer without chemical or genetic modifications and thus preserve the immune stimulating properties of VLPs for easier production of antigen‐specific therapeutic cancer vaccines. Biotechnol. Bioeng. 2015;112: 1102–1110.
- 16 February 2015
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 112 (6) , 1102-1110
Influenza virus‐like particles engineered by protein transfer with tumor‐associated antigens induces protective antitumor immunity
Delivery of antigen in particulate form using either synthetic or natural particles induces stronger immunity than soluble forms of the antigen. Among naturally occurring particles, virus‐like particles (VLPs) have been genetically engineered to express tumor‐associated antigens (TAAs) and have shown to induce strong TAA‐specific immune responses due to their nano‐particulate size and ability to bind and activate antigen‐presenting cells. In this report, we demonstrate that influenza VLPs can be modified by a protein transfer technology to express TAAs for induction of effective antitumor immune responses. We converted the breast cancer HER‐2 antigen to a glycosylphosphatidylinositol (GPI)‐anchored form and incorporated GPI‐HER‐2 onto VLPs by a rapid protein transfer process. Expression levels on VLPs depended on the GPI‐HER‐2 concentration added during protein transfer. Vaccination of mice with protein transferred GPI‐HER‐2‐VLPs induced a strong Th1 and Th2‐type anti‐HER‐2 antibody response and protected mice against a HER‐2‐expressing tumor challenge. The Soluble form of GPI‐HER‐2 induced only a weak Th2 response under similar conditions. These results suggest that influenza VLPs can be enriched with TAAs by protein transfer to develop effective VLP‐based subunit vaccines against cancer without chemical or genetic modifications and thus preserve the immune stimulating properties of VLPs for easier production of antigen‐specific therapeutic cancer vaccines. Biotechnol. Bioeng. 2015;112: 1102–1110.
- 1 June 2014
- Published by Taylor & Francis in Immunotherapy
- Vol. 6 (6) , 675-678
Cancer CARtography: Charting Out a New Approach to Cancer Immunotherapy
Evaluation of: Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra25 (2014). Re...
- 1 June 2014
- Published by Taylor & Francis in Immunotherapy
- Vol. 6 (6) , 675-678
Cancer CARtography: Charting Out a New Approach to Cancer Immunotherapy
Evaluation of: Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra25 (2014). Re...
- 1 January 2014
- Published by Elsevier
- p. 121-141
Lipid-Mediated Cell Surface Engineering
- Open Access
- 24 September 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (1) , 52-63
Allogeneic tumor cell vaccines
The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the investigation of a variety of anti-cancer immunotherapies. The development of novel immunotherapies has been bolstered by the discovery of tumor-associated antigens (TAAs), through gene sequencing and proteomics. One such immunotherapy employs established allogeneic human cancer cell lines to induce antitumor immunity in patients through TAA presentation. Allogeneic cancer immunotherapies are desirable in a clinical setting due to their ease of production and availability. This review aims to summarize clinical trials of allogeneic tumor immunotherapies in various cancer types. To date, clinical trials have shown limited success due potentially to extensive degrees of inter- and intra-tumoral heterogeneity found among cancer patients. However, these clinical results provide guidance for the rational design and creation of more effective allogeneic tumor immunotherapies for use as monotherapies or in combination with other therapies.
- 24 September 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (1) , 52-63
Open AccessAllogeneic tumor cell vaccines
The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the investigation of a variety of anti-cancer immunotherapies. The development of novel immunotherapies has been bolstered by the discovery of tumor-associated antigens (TAAs), through gene sequencing and proteomics. One such immunotherapy employs established allogeneic human cancer cell lines to induce antitumor immunity in patients through TAA presentation. Allogeneic cancer immunotherapies are desirable in a clinical setting due to their ease of production and availability. This review aims to summarize clinical trials of allogeneic tumor immunotherapies in various cancer types. To date, clinical trials have shown limited success due potentially to extensive degrees of inter- and intra-tumoral heterogeneity found among cancer patients. However, these clinical results provide guidance for the rational design and creation of more effective allogeneic tumor immunotherapies for use as monotherapies or in combination with other therapies.
- 16 December 2012
- Published by Taylor & Francis in Immunotherapy
- Vol. 4 (12) , 1795-1798
Taming Dendritic Cells with TIM-3: Another Immunosuppressive Strategy Used by Tumors
Evaluation of: Chiba S, Baghdadi M, Akiba H et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13, 832–842 (2012). The identification of TIM-3 expression on tumor-associated dendritic cells (TADCs) provides insight into another aspect of tumor-mediated immunosuppression. The role of TIM-3 has been well characterized on tumor-infiltrating T cells; however, its role on TADCs was not previously known. The current paper demonstrated that TIM-3 was predominantly expressed by TADCs and its interaction with the nuclear protein HMGB1 suppressed nucleic acid-mediated activation of an effective antitumor immune response. The authors were able to show that TIM-3 interaction with HMGB1 prevented the localization of nucleic acids into endosomal vesicles. Furthermore, chemotherapy was found to be more effective in anti-TIM-3 monoclonal antibody-treated mice or mice depleted of all DCs, which indicated ...
- 16 December 2012
- Published by Taylor & Francis in Immunotherapy
- Vol. 4 (12) , 1795-1798
Taming Dendritic Cells with TIM-3: Another Immunosuppressive Strategy Used by Tumors
Evaluation of: Chiba S, Baghdadi M, Akiba H et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13, 832–842 (2012). The identification of TIM-3 expression on tumor-associated dendritic cells (TADCs) provides insight into another aspect of tumor-mediated immunosuppression. The role of TIM-3 has been well characterized on tumor-infiltrating T cells; however, its role on TADCs was not previously known. The current paper demonstrated that TIM-3 was predominantly expressed by TADCs and its interaction with the nuclear protein HMGB1 suppressed nucleic acid-mediated activation of an effective antitumor immune response. The authors were able to show that TIM-3 interaction with HMGB1 prevented the localization of nucleic acids into endosomal vesicles. Furthermore, chemotherapy was found to be more effective in anti-TIM-3 monoclonal antibody-treated mice or mice depleted of all DCs, which indicated ...